Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO) will feature Ron Cooper, CEO, in presentations at the 2021 Jefferies Virtual Healthcare Conference on June 2 at 9:30 a.m. EDT and the William Blair Annual Growth Stock Conference on June 3 at 12:40 p.m. EDT. Investor meetings are scheduled from June 1-3. Live webcasts can be found on Albireo's Media & Investors page, with replays available for two weeks post-event. Albireo focuses on novel bile acid modulators for rare liver diseases, with its lead product Bylvay under FDA Priority Review for PFIC, aiming for a decision by July 20, 2021.

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, at 9:30 a.m. EDT and William Blair’s 41^st Annual Growth Stock Conference on Thursday, June 3, at 12:40 p.m. EDT. Members of the management team will also host meetings with investors June 1-3.

The live webcast of both presentations will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product candidate, Bylvay, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 trials in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA recently granted Priority Review and set a PDUFA goal date of July 20, 2021. In Europe, the EMA validated MAA. Bylvay is the only IBATi granted accelerated assessment by the EMA. Bylvay has been provisionally accepted by both the FDA and EMA as the brand name for odevixibat. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

When will Albireo Pharma present at the Jefferies Virtual Healthcare Conference?

Albireo Pharma will present on June 2, 2021, at 9:30 a.m. EDT.

What are the details of Albireo's presentation at the William Blair Annual Growth Stock Conference?

The presentation at the William Blair Conference is scheduled for June 3, 2021, at 12:40 p.m. EDT.

How can I access the live webcasts of Albireo Pharma's presentations?

Live webcasts can be accessed on Albireo's Media & Investors page 15 minutes before the scheduled start times.

What is the FDA's decision timeline for Albireo's Bylvay for PFIC?

The FDA has set a PDUFA goal date of July 20, 2021, for Bylvay's review for PFIC.

What is the focus of Albireo Pharma in drug development?

Albireo Pharma focuses on developing novel bile acid modulators to treat rare pediatric and adult liver diseases.